Log In
BCIQ
Print this Print this
 

BMS-986020 (formerly AM152, BMS-986202)

  Manage Alerts
Collapse Summary General Information
Company Bristol-Myers Squibb Co.
DescriptionOral lysophosphatidic acid receptor 1 (LPAR1; (EDG2) antagonist
Molecular Target Lysophosphatidic acid receptor 1 (LPAR1) (EDG2) (LPA1)
Mechanism of ActionLysophosphatidic acid receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationPulmonary fibrosis
Indication DetailsTreat idiopathic pulmonary fibrosis (IPF); Treat lung fibrosis of scleroderma and idiopathic pulmonary fibrosis (IPF); Treat pulmonary fibrosis
Regulatory Designation U.S. - Orphan Drug (Treat idiopathic pulmonary fibrosis (IPF))
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$475.0M

$325.0M

$150.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

03/05/2012

Undisclosed

Undisclosed

Undisclosed

09/08/2011

$475.0M

$325.0M

$150.0M

Get a free BioCentury trial today